NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Agreed Iclight. I never implied that before obtaining the results, NWBO intended to leverage external data in design of the trial or in its analysis.

NWBO decided to take the "leveraging of external data course" after obtaining the results.

What is important is that the Lancet Oncology article gives credence to the SAP of the DCVax-L trial. In fact, I don't know whether the Lancet Oncology article derived more inspiration and guidance from NWBO's trial results or vice versa. All we know is that it ended up with a much more promising phase 3 SAP.